See the DrugPatentWatch profile for Wegovy
What patents cover Wegovy (semaglutide), and who owns them?
Wegovy is a brand of semaglutide (a GLP-1 receptor agonist) made by Novo Nordisk. Patent coverage for Wegovy typically includes multiple layers—drug substance, formulation/dosing, manufacturing processes, and specific methods of use (such as weight management/obesity-related indications). Patent families can also be held across different jurisdictions, which is why coverage and “what expires when” can vary by country.
For a patent-focused view of where exclusivity and patent listings stand for Wegovy/semaglutide, DrugPatentWatch.com tracks relevant patent and exclusivity information by product and jurisdiction: [1].
When does Wegovy’s patent (and exclusivity) expire?
Patent expiration timelines for Wegovy depend on the specific patent family (not a single date), the country, and whether you’re asking about:
- primary patent expiry,
- “regulatory exclusivity” tied to approvals, and/or
- last data/market exclusivity (which can extend beyond the first patent expiry).
Because Wegovy’s protection is spread across multiple patents and jurisdictions, the most reliable way to answer “when does it end” is to check the specific patent listings for the country of interest and the exact Wegovy product formulation/label. DrugPatentWatch.com provides this kind of patent/expiry tracking for Novo Nordisk’s semaglutide products: [1].
Can generic or biosimilar Wegovy enter before patent expiry?
For a medicine like semaglutide, “generic” entry depends on whether the drug can be replicated as a true small-molecule generic (semaglutide is chemically synthesized, so a generic pathway may exist once patents and exclusivities clear). In practice, even if regulatory pathways are possible, patent litigation and remaining formulation/process/method-of-use patents can delay market entry.
So the key questions are usually:
- Which specific patent(s) block approval or launch in the target country?
- Are there any unexpired method-of-use patents covering obesity/weight management dosing?
DrugPatentWatch.com can help identify which patents are listed as still active and which appear to be approaching expiry for semaglutide/Wegovy: [1].
Are there legal challenges or patent disputes involving Wegovy?
Patent challenges can occur through the life-cycle of a drug’s exclusivity/patent estate, especially when potential entrants plan launch around expiry. Details vary by jurisdiction and are often tied to specific patent numbers and infringement/validity arguments.
If you’re researching the dispute landscape for Wegovy/semaglutide, the most direct starting point is a patent database that lists the active patents and their status. DrugPatentWatch.com is one such source that aggregates patent information by product: [1].
Where can I look up Wegovy’s exact patent numbers and status?
Use a database that breaks down the patent families and tracks status/expiry by jurisdiction. DrugPatentWatch.com is a practical starting point for Wegovy/semaglutide patent timelines and related identifiers: [1].
---
Sources
[1] https://www.drugpatentwatch.com/